Target Audience
This activity has been designed to meet the educational needs of anesthesiologists, trauma and critical care specialists, surgical team members, hematologists, blood bankers, and other clinicians interested in surgical hemostasis.



Statement of Need
Bleeding can be a serious complication of surgery and achieving hemostatic balance is a perioperative challenge for the surgical team because of the potential for adverse clinical outcomes due to acquired coagulopathy. This case-based educational program comprises didactic and empirical learning and provides healthcare professionals with the opportunity to hear experts in surgical hemostasis discuss preoperative risk factors for hemostatic complications, common challenges to maintaining optimal surgical hemostasis, and how to evaluate current recommendations for utilizing topical hemostatic agents to control surgical bleeding.



Educational Objectives
After completing this activity, the participant should be better able to:

• Review controversies surrounding the therapeutic options for controlling intraoperative bleeding
• Differentiate topical hemostatic agents used in controlling surgical bleeding
• Explain the benefits and risks of recombinant technology in managing surgical hemostasis
• Explain how to implement current intraoperative protocols to achieve and maintain optimal surgical hemostasis

Faculty
Jeffrey H. Lawson, MD, PhD
Director, Vascular Surgery Research Lab
Director of Clinical Trials in Vascular Surgery
Duke University Medical Center
Durham, North Carolina


Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Method of Participation
During the period May 12, 2009 through May 12, 2010, participants must:

• Read the learning objectives and faculty disclosures
• Study the educational activity
• Complete the posttest by recording the best answer to each question
• Complete the evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.


Fee
There is no fee to participate in or to receive credit for this educational activity.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
Jeffrey H. Lawson, MD, PhD	Consulting Fees: Baxter Healthcare Corporation, Johnson & Johnson, Novo Nordisk Pharmaceuticals, ZymoGenetics, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager	Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Jan Hixon, RN, BSN, MA; Linda Graham, RN, BSN, BA; Jan Schultz, RN, MSN, CCMEP; and Julia Kirkwood, RN, BSN	Have no real or apparent conflicts of interest to report.
ECM: Bart Zoni, Executive Director; Patrick Crowley, Senior Director of Strategic Solutions; Kathleen Krafton, Editorial Services	Have no real or apparent conflicts of interest to report.

Media
Internet


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Cardiovascular & Metabolic Health Foundation (CMH), Educational Concepts in Medicine, and ZymoGenetics, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMH, Educational Concepts in Medicine, and ZymoGenetics, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Commercial Support
This activity is supported by an educational grant from ZymoGenetics, Inc.